Danaher Stock Soars on Q2 Earnings Beat

Key TakeawaysDanaher's second-quarter results beat analysts' expectations on both profit and revenue.CEO Rainer Blair cited "positive momentum" in Danaher's bioprocessing business and "strong performance" in molecular testing subsidiary Cepheid.Danaher affirmed its guidance that non-GAAP core revenue will decline by a low-single-digit percentage year-over-year. Danaher Corp. (DHR) beat analysts' expectations on the top and bottom lines with its second-quarter results, sending shares higher in intraday tradi ...